10.2 RESOLVE
Summary
Patients were randomly assigned to intravitreal ranibizumab 0.3 mg (n=51), intravitreal ranibizumab 0.5 mg (n=51) or sham injection (n=49). In this study, patients underwent a 3 month dose-loading phase after which treatment could be stopped or re-initiated with rescue laser photocoagulation. After the first month, dose-doubling in the 0.05mg arm was permitted.
Quiz Module 10.2
Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account
To validate your answers and keep track of your progress please sign in or register a new account
1. The RESOLVE study showed that:
2. RESOLVE was the first study to allow: